Showing results (131-140 of 2,364) with videos related to
Sort By:
Pageof 237
Clinical Pharmacology and Therapeutics|April 1, 1993
Protein binding and ivermectin estimations in patients with onchocerciasisP O Okonkwo, J E Ogbuokiri, E Ofoegbu, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|January 5, 2002
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoproteinC Pauli-Magnus, S Rekersbrink, U Klotz, et al.Journal of Clinical Pharmacology|March 1, 1987
Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepamU Klotz, W Gottlieb, P P Keohane, et al.Arzneimittel-Forschung|January 1, 1985
A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristicsU Klotz, K E Maier, C Fischer, et al.Zeitschrift Fur Gastroenterologie|November 1, 1994
[Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?]H Allgayer, U Klotz, P Böhne, et al.Biochemical Pharmacology|December 15, 1986
Effect of five structurally diverse H2-receptor antagonists on drug metabolismM Pasanen, P Arvela, O Pelkonen, et al.British Journal of Clinical Pharmacology|July 1, 1990
Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complexE Unseld, G Ziegler, A Gemeinhardt, et al.Pediatric Research|February 7, 2001
Telomeres in neonates: new insights in fetal hematopoiesisU Friedrich, M Schwab, E U Griese, et al.European Journal of Clinical Pharmacology|January 1, 1983
Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in manC Fischer, K Maier, E Stumpf, et al.Clinical Pharmacokinetics|January 1, 1990
Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgeryG Kraus, D R Krishna, D Chmelarsch, et al.Pageof 237